IP Library › Granted Patent US 9,701,627
Granted Patent B2
US 9,701,627 · App. 14/740,674 · Granted Jul 11, 2017

LRRK2 GTP binding inhibitors for treatment of Parkinson's disease and neuroinflammatory disorders

Inventors: Wanli Smith (Bel Air, MD); Fengtian Xue (Potomac, MD); Alexander D MacKerell, Jr. (Baltimore, MD)
Assignee: UNIVERSITY OF MARYLAND, BALTIMORE
C07C311/21C07D213/83C07D295/192
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,701,627
App. No.
14/740,674
Granted
Jul 11, 2017
Kind
B2
Abstract

Compounds, and methods of using the same, are provided as therapies for the treatment leucine-rich repeat kinase-2 (LRRK2)-related disorders including, but not limited to, neurodegenerative and neuroinflammatory disorders, such as Parkinson's Disease.

Claims (6)

1. A compound selected from the group consisting of:

2. The compound of claim 1 , wherein the compound is selected from the group consisting of:

3. The compound of claim 1 , wherein the compound is

4. A pharmaceutical composition comprising a physiologically compatible carrier medium and at least one compound selected from the group consisting of:

5. The pharmaceutical composition of claim 4 , wherein the compound is selected from the group consisting of:

6. The pharmaceutical composition of claim 4 , wherein the compound is

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2015
From: SMITH, WANLI; XUE, FENGTIAN; MACKERELL, ALEXANDER D, JR.
To: UNIVERSITY OF MARYLAND, BALTIMORE
Reel/Frame 035968/0584 →
Continuity (2)
Provisional Application 62012653 · Jun 16, 2014
Related Publication 20150361038A1 · Dec 17, 2015